Grant: Discovery Grants Program - Individual
McGill University
$47,000.00
Dissecting molecular and neuronal implication of a point mutation (p.T8I) of the atypical vesicular glutamate transporter VGLUT3.
FY 2024-25
Summary
Before its release, glutamate is accumulated inside synaptic vesicles by three carriers named VGLUT1-3. The atypical type 3 vesicular glutamate transporter (VGLUT3) is expressed by cholinergic interneurons from the striatum (ChIs). VGLUT3 provides ChIs the ability to transmit with acetylcholine (ACh) in addition to glutamate. VGLUT3 also amplifies ACh vesicular accumulation by a presynaptic mechanism named vesicular synergy. We still poorly understand the mechanistic underlying vesicular synergy. One way to tackle this important issue is to study VGLUT3 coding-variants. This project will use a naturally occuring VGLUT3 human coding variant (p.T8I, change of threonine in position 8 for an isoleucine) to understand how this point mutation alters basic functions of VGLUT3. Recent preliminary results suggest that this variant alters vesicular synergy. We will focus on three main tasks:
Task 1: Anatomical characterization of the VGLUT3-p.T8I mutation. We recently obtained a mouse line expressing the variant (VGLUT3T8I/T8I mice) and will examine the anatomical distribution of VGLUT3-p.T8I using immunohistochemistry and in situ hybridization with probes and antisera developed in our laboratory. Using high resolution STimulated Emission Depletion microscopy (STED), we will characterize the distribution of VGLUT3 relatively to other important synaptic proteins (ACh vesicular transporter, v-SNAREs, calcium channels). We hypothesize that the p.T8I variant does not alter the distribution of the transporter, but that interactions of VGLUT3-p.T8I with other vesicular proteins could be modified.
Task 2: Biochemical characterization of the VGLUT3-p.T8I mutation. We will use VGLUT3T8I/T8I mice to characterize glutamate vesicular accumulation catalyzed by VGLUT3-p.T8I and to confirm changes of vesicular synergy in mutant mice. Uptake assays will be performed in presence of wildtype or mutated peptides to investigate how changing a threonine in position 8 for an isoleucine impacts VGLUT3 activity or vesicular synergy. This task could help to obtain novel and original modulator of VGLUT3 activity.
Task 3: In vivo characterization of ACh efflux in VGLUT3T8I/T8I mice. If the p.T8I variant blunts vesicular synergy, we predict that the release of ACh should be reduced in the striatum of VGLUT3T8I/T8I mice. Using an acetylcholine biosensor (GACh4.3) coupled to fiber photometry we observed that ACh efflux is reduced in the striatum of 2 mutant mice. We will infuse peptides identified in Task 2 and monitor how they impact ACh release in the striatum of WT or VGLUT3T8I/T8I mice.
The short-term objectives of the project are to better understand relationship between structure/function of VGLUT3 and vesicular synergy. These findings will contribute to our long-term objectives which are to clarify the roles of VGLUT3 in neuronal network. Overall, this program will unravel novel and fundamental aspects of brain functions and thereby contribute to progress in natural sciences.
Program
Discovery Grants Program - Individual
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
RGPIN-2024-04617
Name nom
el mestikawy, salah
Department département
psychiatry
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
47000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5403
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Proteins and peptides, amino acids
Research subject fr
Protéines et peptides, acides aminés
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Dissecting molecular and neuronal implication of a point mutation (p.T8I) of the atypical vesicular glutamate transporter VGLUT3.
Keywords
brain; neurones; neurotransmitters; glutamate; vesicular glutamate transporters; vglut3; point mutation; vesicular synergy
Application summary
Before its release, glutamate is accumulated inside synaptic vesicles by three carriers named VGLUT1-3. The atypical type 3 vesicular glutamate transporter (VGLUT3) is expressed by cholinergic interneurons from the striatum (ChIs). VGLUT3 provides ChIs the ability to transmit with acetylcholine (ACh) in addition to glutamate. VGLUT3 also amplifies ACh vesicular accumulation by a presynaptic mechanism named vesicular synergy. We still poorly understand the mechanistic underlying vesicular synergy. One way to tackle this important issue is to study VGLUT3 coding-variants. This project will use a naturally occuring VGLUT3 human coding variant (p.T8I, change of threonine in position 8 for an isoleucine) to understand how this point mutation alters basic functions of VGLUT3. Recent preliminary results suggest that this variant alters vesicular synergy. We will focus on three main tasks:
Task 1: Anatomical characterization of the VGLUT3-p.T8I mutation. We recently obtained a mouse line expressing the variant (VGLUT3T8I/T8I mice) and will examine the anatomical distribution of VGLUT3-p.T8I using immunohistochemistry and in situ hybridization with probes and antisera developed in our laboratory. Using high resolution STimulated Emission Depletion microscopy (STED), we will characterize the distribution of VGLUT3 relatively to other important synaptic proteins (ACh vesicular transporter, v-SNAREs, calcium channels). We hypothesize that the p.T8I variant does not alter the distribution of the transporter, but that interactions of VGLUT3-p.T8I with other vesicular proteins could be modified.
Task 2: Biochemical characterization of the VGLUT3-p.T8I mutation. We will use VGLUT3T8I/T8I mice to characterize glutamate vesicular accumulation catalyzed by VGLUT3-p.T8I and to confirm changes of vesicular synergy in mutant mice. Uptake assays will be performed in presence of wildtype or mutated peptides to investigate how changing a threonine in position 8 for an isoleucine impacts VGLUT3 activity or vesicular synergy. This task could help to obtain novel and original modulator of VGLUT3 activity.
Task 3: In vivo characterization of ACh efflux in VGLUT3T8I/T8I mice. If the p.T8I variant blunts vesicular synergy, we predict that the release of ACh should be reduced in the striatum of VGLUT3T8I/T8I mice. Using an acetylcholine biosensor (GACh4.3) coupled to fiber photometry we observed that ACh efflux is reduced in the striatum of 2 mutant mice. We will infuse peptides identified in Task 2 and monitor how they impact ACh release in the striatum of WT or VGLUT3T8I/T8I mice.
The short-term objectives of the project are to better understand relationship between structure/function of VGLUT3 and vesicular synergy. These findings will contribute to our long-term objectives which are to clarify the roles of VGLUT3 in neuronal network. Overall, this program will unravel novel and fundamental aspects of brain functions and thereby contribute to progress in natural sciences.